RiverPark Advisors’s Tevogen Bio Holdings TVGN Stock Holding History

RiverPark Advisors’s Portfolio TVGN Stock Details TVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,500	Closed	-$1.81M	–	69
2022 Q4	$1.81M	Hold	3,500	–	–	0.86%	52
2022 Q3	$1.78M	Hold	3,500	–	–	0.58%	65
2022 Q2	$1.75M	Hold	3,500	–	–	0.56%	53
2022 Q1	$1.75M	Buy	+3,500	New	+$1.74M	0.32%	67

Other funds holding TVGN

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RiverPark Advisors's TVGN Position: Q1 2023 in Review

RiverPark Advisors sold out of Tevogen Bio Holdings (TVGN) in Q1 2023, closing a stake of 3,500 shares — an estimated $1.81M sold.

RiverPark Advisors first reported a position in TVGN in Q1 2022 and held it in 4 quarters. The position peaked at $1.81M in Q4 2022. 4 funds tracked by Wall St. Rank hold TVGN as of Q1 2023.

RiverPark Advisors reported no remaining Tevogen Bio Holdings position as of Q1 2023 after selling out during the quarter.
RiverPark Advisors sold 3,500 Tevogen Bio Holdings shares in Q1 2023, an estimated $1.81M.
RiverPark Advisors first reported a position in Tevogen Bio Holdings in Q1 2022 and held it in 4 quarters.
RiverPark Advisors's Tevogen Bio Holdings position peaked at $1.81M in Q4 2022.
4 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2023.

Based on RiverPark Advisors's 13F filing for Q1 2023, filed 3 May 2023.